Skip to navigation Skip to content

News

Share

National MS Society partners in development of an exploratory therapy aimed at protecting the nervous system and repairing myelin

January 13, 2015

The National MS Society has partnered with Bionure, Inc. to accelerate the development of its novel neuroprotective and remyelinating compound, called BN201. Under this agreement, the National MS Society through Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable the company to gather data needed to support a request to the FDA to conduct a Phase 1 clinical study in acute optic neuritis, an eye disorder that is often a first sign of multiple sclerosis.

Speeding treatments to people with MS requires bold leadership, tenacity and financial support at every stage of the research process. As an important part of the Society’s research infrastructure, investments through Fast Forward focus on closing the gap between promising discoveries and the commercial development necessary to get new treatments to people with MS.

Read more about this partnership in Multiple Sclerosis News Today
Read more about research to repair the nervous system
Read more about the Society’s commercial research investments
 

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.